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Physiology and Pharmacology
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PURPOSE. The purpose of this study was to test the extent of light damage in different models
of night blindness and apply these paradigms in testing the therapeutic efficacy of
combination therapy by drugs acting on the Gi, Gs, and Gq protein-coupled receptors.
METHODS. Acute bright light exposure was used to test susceptibility to light damage in mice
lacking the following crucial phototransduction proteins: rod transducin (GNAT1), cone
transducin (GNAT2), visual arrestin 1 (ARR1), and rhodopsin kinase 1 (GRK1). Mice were
intraperitoneally injected with either vehicle or drug combination consisting of metoprolol
(b1-receptor antagonist), bromocriptine (dopamine family-2 receptor agonist) and tamsulosin
(a1-receptor antagonist) before bright light exposure. Light damage was primarily assessed
with optical coherence tomography and inspection of cone population in retinal whole
mounts. Retinal inflammation was assessed in a subset of experiments using autofluorescence
imaging by scanning laser ophthalmoscopy and by postmortem inspection of microglia and
astrocyte activity.
RESULTS. The Gnat1/ mice showed slightly increased susceptibility to rod light damage,
whereas the Gnat2/ mice were very resistant. The Arr1/ and Grk1/ mice were
sensitive for both rod and cone light damage and showed robust retinal inflammation 7 days
after bright light exposure. Pretreatment with metoprolol þ bromocriptine þ tamsulosin
rescued the retina in all genetic backgrounds, starting at doses of 0.2 mg/kg metoprolol, 0.02
mg/kg bromocriptine, and 0.01 mg/kg tamsulosin in the Gnat1/ mice. The therapeutic
drug doses increased in parallel with light-damage severity.
CONCLUSIONS. Our results suggest that congenital stationary night blindness and Oguchi disease
patients can be at an elevated risk of the toxic effects of bright light. Furthermore, systems
pharmacology drug regimens that stimulate Gi signaling and attenuate Gs and Gq signaling
present a promising disease-modifying therapy for photoreceptor degenerative diseases.
Keywords: light damage, night blindness, photoreceptors, therapeutics, vision

hotoreceptor degenerative diseases comprise a major cause
of vision loss and blindness.1 Unlike other forms of major
blinding conditions, such as cataract or glaucoma, photoreceptor degenerative diseases unavoidably progress after diagnosis
as they lack treatment options. More than 200 genetic causes
for photoreceptor degenerative diseases have been found to
date (https://sph.uth.edu/retnet/, provided by The University
of Texas Health Science Center, Houston, TX, USA). However,
the most common photoreceptor degenerative condition, agerelated macular degeneration, is multifactorial, often sporadic,
and generally cannot be delineated to a single cause.2
Therefore, a generic treatment option for these diseases, rather
than correction of a single pathological entity, is highly
desirable. One generic treatment strategy is neuroprotective
therapy intended to combat neurodegenerative brain diseases
regardless of their underlying causative mechanisms.3 Such a
disease-modifying treatment strategy does not intend to correct

P

the primordial cause of disease but, instead, aims at blocking
the key pathological pathway(s) that drive cell dysfunction and
death.
One recently proposed disease-modifying treatment strategy
for retinal degeneration relies on systems pharmacology in
which a combination of drugs targets several subtypes of G
protein-coupled receptors (GPCRs) simultaneously, specifically
the Gs-, Gi-, and Gq-coupled receptors.4,5 Gs- and Gi-coupled
receptors both regulate adenylate cyclase. Agonism at the Gscoupled receptor increase the activity of adenylate cyclase,
leading to increased turnover of cAMP, whereas agonism at the
Gi-coupled receptor has an opposite inhibitory effect. The Gqcoupled receptor–signaling pathway differs from Gs- and Gicoupled receptors in that it signals via the phospholipase C
pathway eventually leading to Ca2þ release from the endoplasmic reticulum. However, the Gs-, Gi-, and Gq-coupled receptors’
signaling effects converge as intracellular cAMP levels modulate
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TABLE 1. Summary of Mouse Model Genotypes
Mouse Strain

Background

Pigment

Rpe65 Phenotype

Original Reference

Gnat1 mutant
Gnat2 mutant
Grk1 mutant
Arr1 mutant
BALB/cJ wild-type

129S1/SvlmJ
C57BL/6J
129S1/SvlmJ
C57BL/6J
n.a.

Agouti
Black
Agouti
Black
Albino

Leucine at 450 residue
Methionine at 450 residue
Methionine at 450 residue
Methionine at 450 residue
Leucine at 450 residue

Calvert et al. 200015
Ronning et al. 201816
Chen et al. 199918
Xu et al. 199722
n.a.

n.a., not applicable.

Ca2þ levels and vice versa.6 This systems pharmacology
approach takes into account the cooperation, flexibility, and
redundancy of the aforementioned biochemical pathways and
decreases the cells’ propensity to compensate toward homeostasis if only one of the elements is targeted.4 Indeed, it was
previously shown that simultaneous administration of a Gireceptor agonist (bromocriptine [BRM]) and Gs- and Gqreceptor antagonists (metoprolol [MET] and tamsulosin
[TAM], respectively) lead to a stronger therapeutic effect
than a sum of their parts (i.e., synergistic effect).7
The first steps of vision begin with the conversion of
photons at visible wavelengths of light into electrical signals
in the retina.8 Once a photon reaches the retina and is
absorbed by rhodopsin in rod photoreceptors, a reaction is
triggered in which rhodopsin’s chromophore 11-cis-retinal is
photoisomerized to all-trans configuration activating the
rhodopsin molecule.9 The activated rhodopsin makes repeated contacts with multiple G-protein transducins, catalyzing
their activation, which in turn starts a cascade leading to
hyperpolarization of the photoreceptor. Fast recovery from
light activation requires a rapid turnoff mechanism that is
achieved by rhodopsin’s partial inactivation by phosphorylation catalyzed by rhodopsin kinases. Once visual arrestin
binds to the phosphorylated rhodopsin, the visual pigment is
fully inactivated.10 Proper functioning of the phototransduction cascade, including its efficient shutoff, is a prerequisite
for normal vision and a healthy retina. In this study, we
investigated the extent to which genetic knock-outs of rod
and cone transducin (Gnat1 and Gnat2, respectively),
rhodopsin kinase 1 (Grk1), and visual arrestin 1 (Arr1, SAG)
predispose mice to the damaging effects of light. Furthermore, we simultaneously tested if the previously effective
systems pharmacology-based therapy in the Stargardt disease
model7,11,12 could also prevent light damage exacerbated by
defects in the phototransduction cascade. Herein we demonstrate that a genetic knock-out of Gnat1, associated with
congenital stationary night blindness,13 slightly increases the
susceptibility to light damage in mice, and this can be fully
prevented by pretreatment with METþBRMþTAM. Light
damage in Arr1 and Grk1 knock-out mice, both associated
with Oguchi disease,14 was extremely robust, but could also
be fully prevented with increasing doses of METþBRMþTAM.

MATERIALS

AND

METHODS

Animals
All experiments were approved by the Institutional Animal
Care and Use Committees at Case Western Reserve University
(IACUC Protocol 2014-0071) and University of California Irvine
(IACUC Protocol AUP18-124) and were conducted in accordance with the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthalmic and Visual Research.
Four genetically engineered mouse lines associated with
human retinal diseases caused by defective function of

Downloaded from iovs.arvojournals.org on 05/20/2019

phototransduction proteins, namely congenital stationary night
blindness (Gnat1/), achromatopsia (Gnat2/), and Oguchi
disease (Grk1/ and Arr1/ mice), were used in this study. All
experiments were performed in 5- to 10-week-old male and
female mice. Mice were maintained at ad libitum feeding and
12 hour/12 hour light-dark cycle unless otherwise noted.
Gnat1/ mice were generated on a mixed background.15
Gnat1/ mice carried a wild-type (WT) Rpe65 gene (Leucine
at residue 450). Gnat2/ mice on a C57BL/6J background
were a kind gift from Dr. Marie Burns (University of California,
Davis, CA, USA).16 Grk1/ and Arr1/ mice were obtained
from Washington University (St. Louis, MO, USA).17 The
Grk1/ mice were originally generated in a C57/B6 background,18 but were later backcrossed to a 129S1/SvlmJ
(https://www.jax.org/strain/002448, provided by The Jackson
Laboratory, Bar Harbor, ME, USA) background. The Arr1/
mice were on a C57BL/6J background (https://www.jax.org/
strain/000664, provided by The Jackson Laboratory). The
Grk1/, Arr1/, and Gnat2/ mice carried the Met450
variant of RPE65, which is a ‘protective’ variant compared to
Leu450 variant.19,20 Grk1, Arr1, Gnat1, and Gnat2 genotypes
and Leu versus Met amino acid conversion at residue 450 in the
Rpe65 gene was tested by PCR. WT BALB/cJ albino mice
(https://www.jax.org/strain/000651) were used to compare
the extent of light damage to Gnat1/, Grk1/, and Arr1/
mice as BALB/cJ mice are commonly used in similar
experiments.21 Table 1 summarizes the background of mouse
models used in this study.15,16,18,22

Bright Light Exposure (BLE) and Drug Therapy
We used acute BLE to induce rapid photoreceptor degeneration in mice. After an overnight dark adaptation, the mice were
intraperitoneally (i.p.) injected with either drug solution or
vehicle (2% dimethyl sulfoxide, 2% propylene glycol, and 96%
saline; 150 ll volume), and their pupils were dilated with 1%
tropicamide eye drops under dim red light conditions. The
mice were maintained dark adapted, and 0.5 hours after the
injection, they were transferred to fresh Plexiglas home cages
surrounded by LED flood lights (85–265 V, 100 W, 6500 K color
temperature). These LEDs delivered the BLE. Luminance
measured at the center of the cage was set at 12.5 klux or
25 klux when the light sensor was positioned upward (L203
Photometer; Macam Photometrics Ltd., Livingston, UK). Freely
moving mice (2–4 per exposure cage) were exposed to bright
light for 0.5 hours or 1 hour and were transferred back to the
vivarium thereafter.
For systems pharmacology–based therapy,7 we used a
combination of the following three GPCR drugs: MET, BRM,
and TAM. MET and TAM were purchased from TCI America
(Portland, OR, USA). BRM was purchased from Enzo Life
Sciences (Farmingdale, NY, USA). The drugs were always
administered half an hour prior to the induction of BLE as a
combination of the three drugs in a volume of 150 ll. The
number of replicates in each drug experiments are presented
in Table 2.
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TABLE 2. Number of Replicates in Each Drug Experiment
Mouse Strain
Gnat1/
Gnat1/
Gnat1/
Gnat1/
Gnat1/
Gnat1/
Gnat1/
Grk1/
Grk1/
Grk1/
Grk1/
Arr1/
Arr1/
Arr1/
Arr1/

MþBþT Dose (mg/kg),
or Vehicle

BLE* Parameters

n (OCT/Flat Mount)

Data Presented

Vehicle
0.2-0.02-0.01
1-0.1-0.05
10-1-0.5
Vehicle
10-1-0.5
50-5-2.5
Vehicle
1-0.1-0.05
10-1-0.5
50-5-2.5
Vehicle
1-0.1-0.05
10-1-0.5
30-3-1.5

12.5 klux, 0.5 hours
12.5 klux, 0.5 hours
12.5 klux, 0.5 hours
12.5 klux, 0.5 hours
25 klux, 1 hour
25 klux, 1 hour
25 klux, 1 hour
12.5 klux, 0.5 hours
12.5 klux, 0.5 hours
12.5 klux, 0.5 hours
12.5 klux, 0.5 hours
12.5 klux, 0.5 hours
12.5 klux, 0.5 hours
12.5 klux, 0.5 hours
12.5 klux, 0.5 hours

7/7
6/7
6/5
5/4
5/4
5/4
4/4
6/7
6/6
6/7
5/5
8/7
5/5
6/6
5/5

Figure 3M/N
Figure 3M/N
Figure 3M/N
Figure 3M/N
Figure 3O/P
Figure 3O/P
Figure 3O/P
Figure 4A/E
Figure 4A/E
Figure 4A/E
Figure 4A/E
Figure 5A/E
Figure 5A/E
Figure 5A/E
Figure 5A/E

ONL thickness is an average of two eyes, whereas cone preservation analysis is from one eye per mouse.
* BLE, bright light exposure at an average exposure intensity of 12.5 or 25 klux, and 0.5- or 1-hour duration.

Several dosages were used in different experiments, ranging
0.2 to 50 mg/kg (body weight [bw]) for MET, 0.02 to 5 mg/kg
(bw) for BRM, and 0.01 to 2.5 mg/kg (bw) for TAM. A simple
practice guide for dose conversion between animals and
humans suggests a human reference weight of 60 kg.23 A
typical daily dose of MET in the treatment of blood pressure
ranges from 25 to 100 mg (https://www.rxlist.com/, provided
by WebMD, New York, NY, USA), and assuming a 60-kg person,
this equals to ~0.4 to 1.7 mg/kg. The corresponding
calculations for BRM (20–30 mg daily dose for acromegaly)
and TAM (0.4–0.8 mg for prostatic hyperplasia) brings us to
~0.3–0.5 mg/kg and 0.007–0.01 mg/kg, respectively. Thus, the
lowest doses we used in this study are at clinical dose level or
lower, and in our previous mass spectrometry study,12 these
doses given by i.p. injection rendered such low plasma
concentration in mice that they fell below the detection limit.
Rather, 5-fold higher doses at 1 mg/kg MET, 0.1 mg/kg BRM,
and 0.05 mg/kg TAM were needed to bring the drug plasma
concentrations to ~0.1-2 ng/ml range, which is rather small
when compared with the reported therapeutic blood levels for
MET, BRM, and TAM in humans.24–26

In Vivo Retina Imaging by Optical Coherence
Tomography and Scanning Laser Ophthalmoscopy
All mice underwent optical coherence tomography (OCT)
imaging 7 days after BLE. The mice were anesthetized with
ketamine (20 mg/ml, KetaVed, Bioniche Teoranta, Inverin Co,
Galway, Ireland) and xylazine (1.75 mg/ml, Rompun, Bayer,
Shawnee Mission, KS, USA) solution in PBS at a dose of 0.1 to
0.13 ml/25 g (bw) by i.p. injection, and their pupils were
dilated with 1% tropicamide. OCT was performed with a
Bioptigen spectral-domain OCT device (Leica Microsystems
Inc., Buffalo Grove, IL, USA). Four frames of OCT b-scan images
were acquired from a series of 1200 a-scans. Retinal outer
nuclear layer (ONL) thickness was measured 500 lm away
from the optic nerve head (ONH) in four retinal quadrants
(nasal, temporal, superior, and inferior) using a ruler tool in
ImageJ 1.52a software (National Institutes of Health, Bethesda,
MD, USA). For a majority of the analyses, ONL thickness was
averaged over the four retinal quadrants, and this average was
normalized to the average ONL thickness before the induction
of light damage.
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Scanning laser ophthalmoscopy (SLO) was performed to
obtain whole-fundus images in vivo from a subset of mice right
prior to the OCT. We used the Heidelberg Retinal Angiograph II
(Franklin, MA, USA) SLO machine in the autofluorescence
mode for these images, analyzed qualitatively.

Eye Sample Preparation and
Immunohistochemistry
After in vivo imaging, the mice were euthanized by cervical
dislocation. The superior side of the eyes was marked with a
permanent marker, and thereafter the eyes were enucleated.
One eye was inserted into 4% paraformaldehyde (PFA) in PBS,
and the other eye was either fixed similarly in 4% PFA or in
Hartman’s fixative (Sigma Aldrich, St. Louis, MO, USA). The
eyes were kept in Hartman’s fixative for 24 hours and
subsequently embedded into paraffin and sectioned at 7 lm
thickness in nasal-temporal orientation (yields vertical, superior-inferior oriented sections). These sections were stained with
hematoxylin and eosin (H&E). The PFA-fixed eyes were kept in
PFA for 1 hour after enucleation, and subsequently the retina
was dissected away and processed as a whole-mount sample
and then stained using polyclonal goat S-opsin (1:1000 dilution,
custom-made; Bethyl Laboratories, Montgomery, TX, USA) and
polyclonal rabbit M-opsin (1:1000 dilution, cat. NB110-74730;
Novus Biologicals, Littleton, CO, USA) primary antibodies and
fluorescent secondary antibodies (dilution for both 1:500;
donkey anti-goat Alexa Fluor 488, and donkey anti-rabbit Alexa
Fluor 647; Abcam, Cambridge, UK), as described previously.12
A subset of whole-mount retinas were processed to inspect
astrocytes and microglial cells and therefore stained using
monoclonal mouse anti-GFAP (1:500 dilution; Cell Signaling
Technology, Danvers, MA, USA) and polyclonal rabbit anti-Iba1
(1:500 dilution; Wako Chemicals USA Inc., Richmond, VA, USA)
primary antibodies, and fluorescent secondary antibodies
(dilution for both 1:500; Abcam donkey anti-goat Alexa Fluor
488, and donkey anti-rabbit Alexa Fluor 594).

Light and Confocal Microscopy and Cone
Photoreceptor Preservation Analysis
H&E-stained coronal eye cross-section images were captured
using a light-microscope (Olympus FSX100; Olympus, Waltham, MA, USA). Individual images were captured at 203
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magnification and stitched together by the build-in software.
Flat-mount retinas were imaged with a fluorescent lightmicroscope (Leica DMI6000B) equipped with an automated
stage. Individual images were captured at 203 magnification,
and these images were stitched together using MetaMorph 7.8
software (Molecular Devices, Sunnyvale, CA, USA) to create
retinal whole-mount panoramic images by using green
(excitation 480/40 nm) or far red (excitation 620/60 nm)
fluorescence filter channels. Cone-area preservation after BLE
injury was inspected manually from whole-mount panoramic
images. The entire retinal area, ONH area, and damaged area
were visually determined and manually drawn using MetaMorph software’s trace region tool by a researcher blinded as
to the experimental parameters. The damaged area was
determined for both S-opsin and M-opsin positive images, and
the percentage of damaged area compared with the whole
retinal area (ONH area subtracted) was used in the statistical
analyses. The data are presented as cone preservation
percentage compared with baseline. Note that 100% indicates
fully preserved and completely healthy retina in terms of cone
population.
Confocal microscopy was performed using the Leica TCS
SP8 STED microscope, and the images were captured using a
633 oil-immersion objective. A central location of the retina
was scanned throughout its width in 1-lm steps using gate
reference wavelengths 488 nm and 594 nm. A Z-stack of 10
images (10 lm depth) was combined at the depth of the outer
plexiform layer and the retinal nerve fiber layer, representing
microglial cells and astrocytes, respectively.

Statistical Analysis
Statistical analyses were performed using GraphPad Prism 8
software (La Jolla, CA, USA). Two-way repeated measures
analysis of variance (ANOVA) with Geisser-Greenhouse
correction was applied to datasets that had two variables
(retinal location and thickness). One-way ANOVA was applied
to the analyses of average ONL thickness. All ANOVAs were
followed by Bonferroni post hoc tests. Cone-area preservation
data were analyzed by nonparametric Kruskal-Wallis test
followed by the Dunn’s multiple-comparison tests. Data are
presented as means 6 SEM. The level of statistical significance
was set at P < 0.05.

RESULTS
Defective Function of Rod Transducin, but not
Cone Transducin, Exacerbates Light Damage in
Mice
To determine if genetic silencing of rod transducin (GNAT1)
increases light damage susceptibility in mice, we exposed
Gnat1þ/þ, Gnat1þ/, and Gnat1/ female mice to BLE at 12.5
klux for 0.5 hours, performed OCT imaging 7 days later, and
subsequently euthanized the mice and collected the eyes for
histology. Coronal eye cross-sections were prepared for
morphometry analysis. ONL thickness was measured from
both the OCT images and H&E-stained sections. OCT image
analysis revealed that both the heterozygous Gnat1þ/ and
homozygous Gnat1/ mice were slightly more susceptible to
the damaging effect of light than their WT littermates (Fig. 1A;
P < 0.05). Especially damaged quadrants of the retina were
the inferior and temporal sides (Fig. 1A). The histological
cross-sections allowed an inspection at higher resolution and
a comparison of the central and peripheral retina. This
analysis further demonstrated that both Gnat1þ/ and
Gnat1/ were more prone to light damage than Gnat1þ/þ
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mice (Fig. 1B; interaction: P < 0.05). Intriguingly, the
Gnat1þ/ and Gnat1/ mice showed comparable susceptibility to light damage because there was no difference
between these groups in either the OCT (P ¼ 0.61) or
histology image analyses (P ¼ 0.65) of the ONL thickness.
Notable is that the light damage with these experimental
settings was modest and restricted to the central part of the
retina, leaving the peripheral retina intact (for illustrative
examples, see Figs. 1C–E).
We initially did similar experiments as presented previously
using Gnat2/ mice that lack the cone transducin and
therefore cone-mediated phototransduction,16 but found no
effect of BLE (data not shown). Therefore, we doubled the light
intensity to 25 klux and increased the duration of light
exposure to 1 hour. Nevertheless, we did not detect any light
damage 7 days after strong BLE in Gnat2/ mice as
investigated by OCT (Figs. 2C, 2D), histology (Figs. 2E, 2F),
or by cone-population analyses (Figs. 2H, 2J).

Low-Dose METþBRMþTAM Combination Therapy
Alleviates Light Damage in Gnat1/ Mice
We next investigated if a promising retinoprotective therapy
could alleviate or block light damage in Gnat1/ mice. The
mice were subjected to BLE using the following two different
exposure parameters: (1) 12.5 klux of 0.5 hours and (2) 25
klux for 1 hour. The METþBRMþTAM combination was
administered 0.5 hours before the BLE, OCT imaging was
performed 7 days after, and the mice were euthanized and the
eyes collected thereafter. In this dataset, the retinas were
processed as flat mounts and stained against S- and M-opsins
to investigate cone survival. We found that a very small dose
of METþBRMþTAM at 0.2-0.02-0.01 mg/kg, respectively,
provided a significant ~25% protection against ONL thinning
as measured from OCT images (P < 0.05; Fig. 3M). The
preserved cone area also tended to be higher in
METþBRMþTAM–treated (0.2-0.02-0.01 mg/kg) compared
with vehicle-treated mice (Fig. 3N), although this projection
was not statistically significant. However, when the drug
doses were increased 5-fold to 1-0.1-0.05 mg/kg, full cone
preservation was obtained (P < 0.001; Fig. 3N), and we
observed nearly full protection against ONL thinning (P <
0.001; Fig. 3M). A dose of 10-1-0.5 mg/kg METþBRMþTAM
fully protected the Gnat1/ mouse retina from BLE at 12.5
klux for 0.5 hours (P < 0.001, Figs. 3M, 3N).
We continued by increasing the BLE parameters to 25 klux
for 1-hour exposure to test drug efficacy against more severe
light damage in Gnat1/ mice. Indeed, retina flat-mount
images clearly illustrate a larger damage area in a vehicletreated Gnat1/ mouse retina exposed to 25 klux for 1 hour
when compared with a vehicle-treated Gnat1/ mouse retina
exposed to 12.5 klux for 0.5-hour BLE (Figs. 3I, 3K). The same
direction can be observed by comparing ONL thicknesses
(Figs. 4A, 4B vs. 4E, 4F & Figs. 4M, 4O). Nevertheless, a dose of
10-1-0.5 mg/kg METþBRMþTAM provided full cone protection
in 3 of 4 analyzed eyes even at the more intense BLE at 25 klux
for 1 hour (P < 0.01; Fig. 3P). The only retina from a
METþBRMþTAM–treated mouse that had some damage is
illustrated (Fig. 3L) and shows a significantly smaller damage
area than the retina from a vehicle-treated mouse (Fig. 3K).
There was small damage to an ONL layer so that 25% of its
thickness on average was lost despite treatment with 10-1-0.5
mg/kg METþBRMþTAM (Fig. 3O). However, when we
increased the METþBRMþTAM dose to 50-5-2.5 mg/kg,
complete protection to ONL thickness and cone population
was achieved (P < 0.01; Figs. 3O, 3P).
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FIGURE 1. Homozygous and heterozygous knockouts of rod-transducin (Gnat1) slightly increase susceptibility to light damage in mice. (A) ONL
(i.e., photoreceptor nuclei layer) thickness analysis from OCT images taken at 7 days after BLE shows that Gnat1þ/ (blue bars, n ¼ 8) and Gnat1/
(red bars, n ¼ 5) have thinned ONL when compared with Gnat1þ/þ (black bars, n ¼ 7) mice. Geisser-Greenhouse corrected RM ANOVA was used
followed by Bonferroni’s post hoc tests to compare between-subjects main effect: Gnat1þ/þ vs. Gnat1þ/ and Gnat1þ/þ vs. Gnat1/. Significance
denoted by **P < 0.01. (B) Morphometry analysis from histological sections shows that central inferior (Inf) retina is thinned both in Gnat1þ/ (n ¼
7) and Gnat1/ (n ¼ 5) mice in relation to the Gnat1þ/þ (n ¼ 6) mouse, but superior (Sup) retina is relatively spared. Geisser-Greenhouse corrected
RM ANOVA was used followed by Bonferroni’s post hoc tests to compare between-subjects main effect: Gnat1þ/þ vs. Gnat1þ/ and Gnat1þ/þ vs.
Gnat1/. Significance denoted by **P < 0.01 and ***P < 0.001. Post hoc test to compare the genotypes in different locations: #P < 0.05. (C) A
representative sample of H&E stained retinal cross-section from a Gnat1þ/þ mouse. Inferior retina is shown at ONH level in relation to temporalnasal orientation. Red lines illustrate the measurement points of ONL thickness used for statistical analysis in image B. The inset (c1) shows a
magnification image between 600 and 900 lm from ONH, and the asterisk marks the ONL. (D, E) Similar images as C, but from Gnat1þ/ (D and
inset d1) and Gnat1/ (E and inset e1) mice. RGCL, retinal ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; IS, photoreceptor
inner segments; OS, photoreceptor outer segments.

Dysfunctional Rhodopsin Inactivation Caused by
Either Lack of Rhodopsin Kinase or Visual Arrestin
Renders Mice Extremely Sensitive to Light Damage
That Is Alleviated by METþBRMþTAM Treatment
To investigate if phototransduction overdrive, rather than
phototransduction blockade (as presented in the previous
Gnat1/ data), increases light-damage susceptibility, we
continued the BLE experiments using Grk1/ and Arr1/
mice that lack the rhodopsin kinase and visual arrestin 1,
respectively. These mutations lead to dramatically prolonged
rhodopsin inactivation.18,22 In conjunction with light-damage
susceptibility per se, we tested if METþBRMþTAM treatment is
effective in these paradigms as well. OCT imaging revealed an
almost complete destruction of the central retina’s ONL in
vehicle-treated Grk1/ mice (Figs. 4A, 4C), leaving only a few
rows of nuclei occasionally into the superior and/or nasal
central retina (data not shown). Although the cones are
relatively resistant to light damage, the damaged cone area in
flat-mounted retinas in vehicle-treated Grk1/ mice was on
average ~40%. Notably, the variation in cone-damage area after
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bright-light exposure is relatively large, and some mice lost
most of their cones (see Fig. S1 for illustration). The light
damage in the Grk1/ mice was so robust that a modest dose
of METþBRMþTAM at 1-0.1-0.05 mg/kg could not provide a
statistically significant therapeutic effect, although some
tendency for protection could be observed (Figs. 4A, 4E).
Instead, a higher dose of 10-1-0.5 mg/kg protected 50% of the
ONL thickness (P < 0.001; Fig. 4A) and ~95% of the cone area
in retinal flat-mount samples (P < 0.05; Fig. 4E), a result that
indicates that complete cone protection can be achieved with
lower drug doses than that required to retain the full ONL
thickness. Increasing the drug doses to 50-5-2.5 mg/kg fully
protected most retinas from ONL thinning and cone damage (P
< 0.01; Figs. 4A, 4D, 4E, 4H, 4I), and completely blocked the
retinal inflammation caused by BLE in the Grk1/ mice (Figs.
4J–P).
Similar results were obtained in the Arr1/ as with Grk1/
mice, with the only difference that light damage seemed
slightly milder in the Arr1/ mice (inflammatory response
comparison in Arr1/ and Grk1/ in Figs. 4K, 4M, 4O and
Figs. 5K, 5M, 5O). Again, a modest dose of METþBRMþTAM at
1-0.1-0.05 mg/kg could not provide significant retinal protec-
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FIGURE 2. Retinal anatomy analysis by three different methods illustrates resistance to light damage in Gnat2/ mouse. Imaging was performed 1
week after intense BLE at 25 klux for 1 hour BLE. (A, B) OCT images in superior-inferior (A) and temporal-nasal (B) orientations in a wild-type
mouse. (C, D) OCT images in superior-inferior (C) and temporal-nasal (D) orientations in a Gnat2/ mouse. Asterisks highlight the ONL in the
inferior (C) and temporal (D) locations where light damage is typically first observed in pigmented mice. In BLE Gnat2/ mice, these locations
show normal retina morphology. (E) A representative sample of H&E-stained Gnat2/ mouse eye histology. Black quadrangle illustrates the point
at which high magnification image (F) was taken. (F) High-magnification histology image shows completely normal retinal anatomy at the central
inferior retina. (G, H) Flat-mounted wild-type (G, I) and Gnat2/ (H, J) mouse retinas stained against anti M- (green) and S-opsin (blue) antibodies
indicate preserved cone photoreceptor population both in wild-type and Gnat2/ mice. Three replicates showed the same result.

tion against light damage in the Arr1/ mice, although on
average the ONL thickness and preserved cone area were
larger in the drug-treated than vehicle-treated mice (Figs. 5A,
5E). A 10-fold higher dose at 10-1-0.5 mg/kg protected more
than 50% of the ONL thickness (P < 0.001; Fig. 5A) and more
than 95% of the cone area (P < 0.05, Fig. 5E). A dose of 30-31.5 mg/kg practically fully protected the retinas from ONL
thinning and cone damage (P < 0.01; Figs. 5A, 5D, 5E, 5H, 5I).
The METþBRMþTAM treatment was able to block the BLEinduced inflammation also in the Arr1/ mice (Figs. 5J–P).

Summary of Light-Damage Susceptibility
A summary of light-damage susceptibility in the mouse strains
used in this study is shown in Figure 6. A group of WT BALB/cJ
albino mice was added to this analysis to allow the comparison
to this mouse strain commonly used in light-damage studies.
The analysis shows that Gnat2/ mice (black-colored and
carrying methionine mutation at residue 450 in Rpe65) were
completely resistant to light damage, whereas all other mouse
genotypes showed some susceptibility to light damage,
including Gnat1þ/þ mice that were agouti-colored and WT in
terms of the Rpe65 gene (leucine at residue 450 in Rpe65).
When compared with the well-known light-damage susceptible
BALB/cJ albino mice (Leu450-Rpe65 gene), our Arr1/ (blackcolored) and Grk1/ (agouti-colored) mice (both carrying
Met450-Rpe65) showed on average higher, although statistically comparable, susceptibility.

DISCUSSION
GNAT1 mutations are causative for autosomal dominant or
recessive congenital stationary night blindness. However, two
recent clinical reports have implicated the novel type of
homozygous GNAT1 mutations into a progressive retinal
dystrophy.27,28 In Gnat1/ mice, a few rows of photoreceptor
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nuclei are lost within the first weeks of a mouse’s life for an yet
undetermined reason, but thereafter the condition is stationary.15 Using heterozygous and homozygous Gnat1 knock-out
mice, we found that the defective rod phototransduction
increases the retina’s susceptibility to the damaging effects of
light. This was observed as exacerbated thinning of photoreceptor nuclei layer in Gnatþ/ and Gnat1/ mice using two
different imaging modalities: OCT and light microscopy from
eye sections. BLE is commonly used in preclinical research
settings to induce photoreceptor degeneration in susceptible
albino rodents.21,29 On the other hand, BLE can be used to
trigger photoreceptor degeneration in a timely manner in
genetically engineered mouse models of retinal degenerative
diseases.29 Two previously published works suggest increased
susceptibility to light damage in Gnat1/ mice.30,31 Krishnan
et al.31 showed that the expression of a small number of genes,
mostly crystallins, as well as apoptosis were increased in
Gnat1/ mice retinas. Hao and colleagues30 suggested two
distinct pathways for light-induced apoptosis in the retina. The
first is BLE-induced apoptosis that is independent of transducin. Instead, it is mediated upstream by activated rhodopsin
and the subsequent accumulation of toxic visual cycle
byproducts, such as all-trans-retinal.30,32,33 The second apoptotic pathway appears at low light levels and seems to be
primarily dependent on transducin as Gnat1 deletion blocks
low light-induced photoreceptor death in Grk1/ mice by
90%.30 As BLE-induced damage appears to be mostly mediated
upstream of transducin, what then might explain the increased
susceptibility in Gnat1/ mice remains unanswered. Recently,
it was demonstrated that rod phototransduction plays a
significant role in adjusting retinal metabolism to changing
light conditions.34 Researchers showed that retinas extracted
from Gnat1/ mice had a dysfunction in inhibiting O2
consumption and energy metabolism that naturally occur
when ambient conditions change from dark to light. This
suggests that the retina relies on sensory signaling to match
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FIGURE 3. Protection of rods and cones against light damage in Gnat1/ mice. Mice were subjected to BLE (12.5 klux for 0.5 hours, or 25 klux for 1
hour) 1 week prior to imaging. Either drug combination (metoprolol þ bromocriptine þ tamsulosin [MþBþT]) or vehicle was injected intraperitoneally
0.5 hours prior to induction of light damage. Number of replicates are presented in Table 2. (A–D) Representative OCT images from vehicle-treated (A,
B) and drug-treated (C, D) mice that were exposed to BLE at 12.5 klux for 0.5 hours. ONL thickness was measured at all retinal quadrants at 500 lm
distance (green and red capped lines) from ONH, and averaged and normalized to baseline (ONL thickness without BLE) for analysis presented in M
and O. (E–H) Representative OCT images from vehicle-treated (E, F) and drug-treated (G, H) mice that were subjected to BLE at 25 klux for 1 hour. (I–
L) Representative flat-mount retina images show typical S-cone distribution in vehicle-treated (I, K) and drug-treated (J, L) mouse retinas 1 week after
BLE at 12.5 klux for 0.5 h (I, J), and more intense BLE at 25 klux for 1 hour (K, L). Dashed white line illustrates the border between damaged and
healthy site in cone population. All flat-mounted retinas were oriented the same way. (M) Statistical analysis of averaged and normalized (to baseline,
52.0 6 1.0 lm) ONL thickness in vehicle-treated and drug-treated mice subjected to BLE at 12.5 klux for 0.5 hours. (N) Cone population preservation
in flat-mount retinas from mice subjected to BLE at 12.5 klux for 0.5 hours. (O) Statistical analysis of averaged and normalized ONL thickness (to
baseline 52.0 6 1.0 lm) in mice subjected to BLE at 25 klux for 1 hour. (P) Cone population preservation in flat-mount retinas from mice subjected to
BLE at 25 klux for 1 hour. Note that the retinal damage is more severe after 25 klux than 12.5 klux BLE, and a larger dose of drugs is needed to obtain
full retinal protection. Statistical analysis was performed by one-way ANOVA, followed by Bonferroni’s post hoc test. Significance denoted by *P < 0.05,
**P < 0.01, ***P < 0.001. Inf, inferior; Sup, superior; Nas, nasal, Temp, temporal side of the retina.
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FIGURE 4. Protection of the retina against light damage in Grk1/ mice. Mice were subjected to BLE (12.5 klux for 0.5 hours) 1 week prior to
imaging. Drug combination (MþBþT) or vehicle was injected i.p. 0.5 hours prior to induction of light damage. Number of replicates are presented in
Table 2. (A) Averaged and normalized (to baseline, 58.0 6 0.2 lm) ONL thickness as measured at all central retinal quadrants (500 lm from ONH)
from OCT images. (B–D) Representative OCT images at baseline (B, before BLE) and 7 days after BLE in vehicle (C) and (D) MþBþT–treated Grk1/
mouse eyes. Asterisks (protection in B, D) and pound sign (damage in C) highlight the region of interest, that is, ONL. Red line in B represents the
ONL thickness at 500 lm from the ONH. (E) Damaged cone area in S- and M-opsin labeled flat-mount retinas was manually determined (see
Materials & Methods for details). (F–I) Representative flat-mount retina images show typical M- (green) and S-cone (blue) populations in vehicletreated (F, G) and drug-treated (H, I) mouse retinas 1 week after BLE. Dashed white lines illustrate the border between damaged and healthy site in
cone population. Note that MþBþT at a dose 10-1-0.5 mg/kg was able to maintain cone population by ~95%, whereas ONL thickness (representative
of rod population) with this dose was decreased by ~50%. MþBþT 50-5-2.5 mg/kg dose led to full protection in both rod and cone population. (J–L)
Representative autofluorescence fundoscopy images before BLE (J) and 7 days after BLE in vehicle-treated (K) and MþBþT–treated (L) Grk1/
mouse eyes. (M, N) Representative retinal whole mounts showing microglia (anti-Iba1 staining) at the level of the outer plexiform layer. Note the
massive microglial infiltration and amoeboid formation in vehicle-treated mouse retina, whereas the MþBþT–treated mouse retina shows more
stratified microglial morphology. (O, P) Representative retinal whole mounts shows slight astrocyte (anti-GFAP staining) activation in vehicle-treated
mouse retina, but not in MþBþT–treated mouse retina. Statistical analysis was performed by one-way ANOVA, followed by Bonferroni’s post hoc test.
Significance denoted by *P < 0.05, **P < 0.01, ***P < 0.001.
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FIGURE 5. Protection of the retina against light damage in Arr1/ mice. The design of layout is the same as in Figure 4. Number of replicates are
presented in Table 2. (A) Averaged and normalized (to baseline, 59.4 6 0.3 lm) ONL thickness at central retina. (B–D) Representative OCT images
at baseline (B, before BLE) and 7 days after BLE in vehicle-treated (C) and (D) MþBþT–treated Arr1/ mouse eyes. (E) Damage area in S- and M-opsin
labeled flat-mount retinas. (F–I) Representative flat-mount retina images show typical M- (green) and S-cone (blue) distributions in vehicle-treated (F,
G) and drug-treated (H, I) mouse retinas 1 week after BLE. Dashed white line illustrates the border between damaged and healthy site in cone
population. (J, L) Representative autofluorescence fundoscopy images before BLE (J) and 7 days after BLE in vehicle-treated (K) and MþBþT–treated
(L) Arr1/ mouse eyes. (M, N) Representative retinal whole mounts showing microglia (anti-Iba1 staining) at the level of the outer plexiform layer.
Note the amoeboid microglia morphology in the vehicle-treated mouse retina and normal stratified morphology in the MþBþT–treated retina. Note
also that the microglia activation was milder in BLE Arr1/ compared to Grk1/ mice (compare to Fig. 4M). (O, P) Representative retinal whole
mounts show a modest astrocyte (anti-GFAP staining) activation in the vehicle-treated mouse retina, but not in MþBþT–treated mouse retina.
Statistical analysis was performed by one-way ANOVA followed by Bonferroni’s post hoc test. Significance denoted by *P < 0.05, **P < 0.01, ***P <
0.001.
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FIGURE 6. Summary of light-damage susceptibility in mouse strains used in this study. All mice were exposed to BLE at 12.5 klux light for 0.5 hours,
and ONL thickness was determined from OCT images 7 days after BLE (Gnat2/, n ¼ 3; Gnat1þ/þ, n ¼ 13; Gnat1/, n ¼ 8; BALB/c, n ¼ 8; Arr1/,
n ¼ 8; Grk1/, n ¼ 6). The retinas were processed as flat mounts 8 days from BLE and stained against opsin antibodies. Cone-area preservation was
evaluated from panoramic retina images (Gnat2/, n ¼ 3; Gnat1þ/þ, n ¼ 7; Gnat1/, n ¼ 4; BALB/c, n ¼ 9; Arr1/, n ¼ 7; Grk1/, n ¼ 7). Onesample t-test was used to test if ONL thickness or preserved cone area was significantly different from 100% (baseline). Significance denoted by *P <
0.05, **P < 0.01, *P < 0.001.

energy production to demand rather than the direct coupling
of the two. During BLE, the retina and adjacent retinal pigment
epithelium are bombarded with intermediates from the visual
cycle such as all-trans-retinal. If clearance of all-trans-retinal
does not match production, toxicity occurs via oxidative
stress.35 Therefore, the first survival strategy for the retina
would be visual cycle shutoff. Indeed, both light and circadian
daytime have been shown to partially suppress the rod visual
cycle, which likely provides protection from light damage
during day time.36 Second, metabolic suppression and a
decrease in oxidative stress are protective for the retina,37,38
even if direct evidence from light-toxicity experiments is
missing. In the absence of normal rod phototransduction, the
metabolic suppression at dark-light switch is dysfunctional,34
providing one hypothesis for the subtly increased susceptibility
to light damage in Gnat1 knock-out mice. However, we were
surprised that even the heterozygous Gnat1 knock-out mice
showed increased susceptibility to light damage, a finding that
to the best of our knowledge has not been shown previously.
In the original characterization of Gnat1 knock-out mice,
Calvert et al.15 showed that Gnatþ/ mice had very similar
phototransduction when compared with WT mice, although
the mean sensitivity tended to be lower and displayed an
unusually high variability. Their immunoblotting analysis
indicated that the a-subunit of transducin, which was the
target of knock-out, was decreased only by ~30% in Gnatþ/
retinas, whereas 100% loss was found Gnat/ retinas. Instead,
a compensatory increase in expression of b-subunit of
phosphodiesterase was equal in Gnat1þ/ and Gnat/ retinas.
These data imply that the mechanism of increased light-damage
susceptibility in Gnat1þ/ and Gnat1/ mice can be very
complex.
In our study, a lack of phototransduction in the cone
pathway did not increase sensitivity to light damage as
investigated by using Gnat2/ mice. Because only 3% of
photoreceptors in mouse retina are composed of cones and
the rest are rods, it is conceivable that cone phototransduction
has a negligible effect on metabolic shift in the retina.
However, our experiment in Gnat2/ mice was not completely conclusive as these mice were on the C57BL/6J
background, and we could not induce any light damage in
either C57BL/6J (data not shown) or Gnat2/ mice (both
carrying the protective Met450 mutation in Rpe6520) even at
intense light exposure at 25 klux for 1 hour. Other researchers
have not found any signs of spontaneous rod or cone
degeneration in Gnat2/ mice, although full suppression of
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cone phototransduction in these mice is present.16 In humans,
GNAT2 mutations are rare conditions that can cause achromatopsia and/or cone-rod dystrophy.39,40
Regardless of the cause of increased light damage in Gnat1
knock-out mice, we were able to prevent it by administering a
combination of MET, BRM, and TAM at a relatively low dose
pretreatment before BLE. In a report by Chen et al.,7
synergistic therapeutic effect against photoreceptor death
was achieved when MET, BRM, and TAM were administered
simultaneously. The simultaneous administration of several
GPCR drugs that inhibit second-messenger signaling decreases
the cells’ propensity for homeostatic compensation compared
to the situation when only one class of GPCRs is targeted.4 This
enables a stronger therapeutic effect with smaller doses and
thus decreased risk of adverse effects. MET is a selective b1receptor blocker and widely used in the treatment of
cardiovascular conditions such as high blood pressure. BRM
is mainly used for its agonistic actions on the dopamine family
2 receptors (i.e., D2, D3, and D4) and is also clinically available.
TAM is a selective a1-receptor antagonist widely used to treat
benign prostatic hyperplasia. Previous research has shown that
all of these drugs can prevent light damage in Abca4/Rdh8
double knock-out mice when given as a high-dose monotherapy.7 Although the protective mechanism has not yet been
systemically established, it is proposed that decreased secondmessenger signaling accounts for this.4,35 Antagonism at the Gscoupled receptor (MET’s action) and agonism at the Gi-coupled
receptor (BRM) both decrease the formation of cAMP from ATP
via inhibition of adenylate cyclase. TAM inhibits Gq-coupled
receptor mediated signaling and leads to decreased Ca2þ
release from the endoplasmic reticulum to cytosol via the
phospholipase C/inositol triphosphate pathway. Elevated
intracellular levels of coregulated second messengers such as
Ca2þ and cyclic nucleotides can all be cytotoxic by multiple
mechanisms.41–43 Our present data show that low doses of 0.2
mg/kg MET, 0.02 mg/kg BRM, and 0.01 mg/kg TAM partially
protected Gnat1/ mouse retinas from light damage. Even if
direct translation of dosages from mouse experiments to
clinical practice is troublesome, we can speculate that these
doses are in similar range, or lower, than is generally used with
MET, BRM, and TAM for their primary clinical indications (see
the ‘‘Bright Light Exposure (BLE) and Drug Therapy’’ section).
Predisposition to light damage in Grk1/ and Arr1/ mice
is known from previous literature.18,22,30,31 The mechanism
leading to this can be directly delineated to dramatically
prolonged activation of rhodopsin. The visual disorder
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associated with both GRK1 and ARR1 mutations is called
Oguchi disease and is clinically characterized by a goldenyellow discoloration of the fundus that disappears after
prolonged dark adaptation.44 Oguchi disease is mostly considered a stationary condition; however, retinal degenerative
changes, sometimes severe, have been observed in patients
affected with various types of GRK1 or ARR1 mutations.45–47
In the current study, the severity of light damage in Grk1/
and Arr1/ was still surprising to us, especially considering
that our Grk1/ and Arr1/ mice carried the Met450
conversion in Rpe65 gene, a mutation that is known to
decrease light damage significantly.20 We compared the light
damage in Grk1/ and Arr1/ mice to Balb/C albino mice
(carrying Leu450 isoform of Rpe65) frequently referenced in
publications.21 The same BLE method caused damage at a
similar range in the Grk1/ and Arr1/ mice when compared
with the Balb/C mice, although the Grk1/ and Arr1/ mice
should be relatively protected because of their pigmentation
and protective Met450 variant of Rpe65. The Grk1/ mice
displayed massive microglia infiltration and activation 7 days
after BLE as shown by intense fundus autofluorescence by SLO
imaging and by postmortem immunohistochemistry analyses.
A parallel but slightly milder finding was observable in the
Arr1/ mouse retinas after BLE. The fact that our Grk1/
mice were agouti-colored and Arr1/ mice were black can
explain this difference because the amount of pigment is
known to positively correlate with protection of light
damage.48 Despite the dramatic light damage in the Grk1/
and Arr1/ mice, we could prevent the associated cone death
almost fully with a dose of 10 mg/kg MET, 1 mg/kg BRM, and
0.5 mg/kg TAM. Notable is that the same dose protected only
~50% of ONL thickness, which is more representative of rod
faith.12 In light damage and in most genetic causes of
photoreceptor degeneration, the rods are primarily dying
followed by cone death.49 As the human daily life consists
mostly of activities in day light or under artificial light, the
protection of cones is of primary importance and could suffice
to retain most vital visual functions, such as visual acuity, even
if the rods were partially lost.
In summary, our study provide confirmation that defective
rod phototransduction by the Gnat1 knock-out in mice increases
their sensitivity to BLE damage, and therefore light exposure can
be a risk factor for patients carrying GNAT1 mutations. Patients
with Oguchi disease could be at an even higher risk of these
damaging light effects as the Grk1/ and Arr1/ mice were
extremely sensitive to light damage. Interestingly, Oguchi disease
patients, and congenital stationary night blindness patients in
general, frequently experience a strong photophobia.50 Collectively, our results together with recent clinical findings27,28,45–47
suggest that the stationary nature of diseases caused by GNAT1,
SAG (Arr1), and GRK1 mutations should be taken with caution.
We also report that the systems pharmacology–based therapy by
coadministration of Gs- (e.g., adrenergic b1-blockers) and Gqcoupled (e.g., adrenergic a1-blockers) receptor antagonists and
Gi-coupled receptor agonists (e.g., dopamine type-2 receptor
agonists) may provide a potential disease-modifying treatment
strategy for retinal degenerative diseases. In this report, we
demonstrated its protective effects in Gnat1/, Grk1/, and
Arr1/ mouse models, which all carry defects in distinct parts of
the rod phototransduction cascade. Future studies will focus on
the investigation of systems pharmacology–based therapeutic
effects and mechanisms in chronic disease models paving the
way to clinical trials.
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